PWMG
ALXN

Prestige Wealth Management Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Prestige Wealth Management Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-58
Closed -$11K – 1076
2021
Q2 		$11K Buy
58
+8
+16% +$1.37K ﹤0.01% 474
2021
Q1 		$8K Sell
50
-35
-41% -$5.41K ﹤0.01% 537
2020
Q4 		$13K Buy
85
+73
+608% +$9.38K ﹤0.01% 417
2020
Q3 		$1K Hold
12
– – ﹤0.01% 866
2020
Q2 		$1K Sell
12
-16
-57% -$1.7K ﹤0.01% 872
2020
Q1 		$3K Buy
+28
New +$2.75K ﹤0.01% 607
2019
Q1 		– Sell
-105
Closed -$10K – 1237
2018
Q4 		$10K Buy
+105
New +$12.4K 0.01% 444

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return